Related Experiment Video

Updated: May 17, 2026

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis

Daniel J Smith1, Iain L Lamont, Greg J Anderson

  • 1The Prince Charles Hospital, Brisbane.

The European Respiratory Journal
|November 13, 2012
PubMed

Insights

This study reviews how iron impacts Pseudomonas aeruginosa biofilm infections, particularly in cystic fibrosis patients. Targeting iron acquisition offers a promising therapeutic strategy against these difficult-to-treat bacterial infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pulmonary Medicine

Background:

  • Pseudomonas aeruginosa is an opportunistic pathogen causing severe human infections.
  • P. aeruginosa forms biofilms, conferring resistance to antibiotics and host defenses.
  • Iron is crucial for P. aeruginosa virulence and regulates quorum sensing and gene expression.

Purpose of the Study:

  • To review the role of iron availability in P. aeruginosa lung infections.
  • To explore P. aeruginosa biofilm infections in cystic fibrosis as a model.
  • To discuss novel therapeutics targeting iron acquisition systems.

Main Methods:

  • Literature review focusing on iron metabolism in P. aeruginosa.
  • Analysis of P. aeruginosa biofilm formation and virulence.
  • Examination of therapeutic strategies targeting iron acquisition.

Main Results:

  • Iron significantly influences P. aeruginosa behavior, including biofilm formation and virulence.
  • Iron acquisition systems are critical for P. aeruginosa infection success.
  • Cystic fibrosis lung infections serve as a model for chronic P. aeruginosa biofilm infections.

Conclusions:

  • Perturbing iron acquisition systems is a potential therapeutic approach for P. aeruginosa infections.
  • Translating in vitro therapies to clinical settings requires overcoming specific barriers.
  • Further research is needed to develop effective treatments for chronic P. aeruginosa pulmonary infections.

More Related Videos

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Gene Regulation in Microbial Communities: Quorum Sensing01:28

Gene Regulation in Microbial Communities: Quorum Sensing

Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: